DOCSLIB.ORG

Interactions Among Hageman Factor, Plasma Prekallikrein, High

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interactions Among Hageman Factor, Plasma Prekallikrein, High Proc. Natl. Acad. Sci. USA Vol. 76, No. 2, pp. 958-961, February 1979 Medical Sciences Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent (Factor XII/Fletcher factor/Fitzgerald factor/Factor XI) OSCAR D. RATNOFF AND HIDEHIKO SAITO Department of Medicine, The School of Medicine, Case Western Reserve University, Cleveland, Ohio; and University Hospitals of Cleveland, Cleveland, Ohio 44106 Contributed by Oscar D. Ratnoff, December 1, 1978 ABSTRACT To investigate the earliest steps of the intrinsic M sodium citrate, and bovine PTA-deficient plasma was from clotting pathway, Hageman factor (Factor XII) was exposed to blood containing 1/9th vol of 0.13 M sodium citrate buffer (pH Sephadex gels to which ellagic acid had been adsorbed; Hage- 5.0). A standard pool of normal adult plasmas (14) was said to man factor was then separated from the gels and studied in the 1 and PTA. fluid phase. Sephadex-ellagic acid-exposed Hageman factor, contain unit/ml each of HF, PK, HMWK, whether purified or in plasma, activated plasma thromboplastin Plasmas simultaneously deficient in PTA and other factors antecedent, but only when high molecular weight kininogen were prepared by incubating Fletcher or Fitzgerald trait was present. In the absence of plasma prekallikrein, maximal plasmas for 1 hr at 370C with specific immunoglobulins. Plas- activation of plasma thromboplastin antecedent was slightly mas simultaneously deficient in PK and other factors were delayed in plasma, a delay not observed with similarly treated prepared from Fletcher trait plasma. Absorption with specific purified Hageman factor. Thus, high molecular weight kini- immunoglobulins removed more than 99% of PTA and PK, and nogen was needed for expression of Hageman factor's clot- more than 98% of HMWK and plasminogen; immunoabsorp- promoting properties and plasma prekallikrein played a minor role in the interaction of ellagic acid-treated Hageman factor tion did not bring about activation of HF. The mixtures were and plasma thromboplastin antecedent. adsorbed with 1/50th vol of Cy-alumina gel (Calbiochem) for 10 min at room temperature to remove vitamin K-dependent Plasma exposed to negatively charged agents clots through clotting factors, centrifuged at 2000 X g for 10 min to sediment reactions of the intrinsic pathway of thrombin formation. The the Cy-alumina gel and insoluble antigen-antibody precipitates, first step in this pathway is activation of Hageman factor (HF, and stored at -70'C until used. Factor XII). Indirect evidence implies that negatively charged Plasmas simultaneously deficient in HF and other clotting substances bring about a conformational change in HF needed factors were prepared by immunoabsorption of Fletcher or for its clot-promoting activity (1-3). Recent studies suggest that Fitzgerald trait plasmas on columns of insoluble immuno- activation of human (4) and bovine (5) HF also involves its globulin against HF covalently bonded to cyanogen bromide- proteolytic scission within an internal disulfide loop. Once ac- activated agarose (Pharmacia) (15) and elution with barbital/ tivated, HF activates plasma thromboplastin antecedent (PTA, saline buffer (0.025 M sodium barbital in 0.125 M sodium Factor XI). The roles of plasma prekallikrein (PK, Fletcher chloride, pH 7.5). (Unless otherwise noted, the term "buffer" factor) and high molecular weight kininogen (HMWK, Fitz- refers to this buffer.) The contents of tubes containing protein gerald, Williams, Flaujeac, or Reid factor) in the intrinsic were pooled, 1/50th vol of 0.5 M sodium citrate buffer (pH 5.0) pathway are not fully elucidated. This pathway is impaired in was added, and the solution was concentrated to its original plasmas deficient in either PK (6) or HMWK (7). In purified volume by ultrafiltration through an Amicon PM-10 membrane systems, however, while activation of PTA requires the presence (Amicon Corporation, Lexington, MA) at 4VC. Simultaneous of HMWK (8-11), PK is not a necessary reactant (12, 13). One deficiency of HF, PK, and plasminogen was produced by in- explanation for the difference between plasma and purified cubation of immunoglobulin against plasminogen with Fletcher HF thus obscuring trait plasma for 1 hr at 370C before filtration through insoluble systems is that is altered during purification, anti-HF. Alternatively, plasma was depleted of more than 98% a need for PK. of plasminogen by filtration through lysine-agarose (16). The We have reexamined the early steps in the intrinsic pathway treated plasmas, containing no detectable HF, were stored at to determine whether activation of HF in plasma requires PK -70°C in silicone-coated polyethylene containers until used. or HMWK. Plasma containing HF, or purified HF, acquired A crude immunoglobulin fraction was separated from normal clot-promoting properties upon exposure to ellagic acid ad- rabbit serum or from monospecific rabbit antisera to human sorbed to Sephadex gels. Expression of these properties required HF (17), PTA (18), kallikrein (19), HMWK (13), and plas- the presence of HMWK but not PK. minogen (Behring, Sommerville, NJ) (20). The volume of an- tiserum needed was determined by incubating dilutions of MATERIALS AND METHODS immunoglobulin in buffer with equal volumes of pooled plasma Normal human plasma and plasma from individuals with for 1 hr at 37°C and measuring the residual titer of the specific Hageman trait, Fitzgerald trait (HMWK deficiency), and PTA factor. deficiency were separated from venous blood containing 1/50th Ellagic acid, synthesized by James D. Crum (21), was dis- vol of 0.5 M sodium citrate buffer (pH 5.0) (14). Fletcher trait solved at 0.1 mM in 0.05 M glycine buffer (pH 10.0), adjusted (PK deficiency) and Christmas disease (Factor IX deficiency) to pH 7.5 with 1 M sodium acetate buffer (pH 4.8), and filtered plasmas were prepared from blood containing 1/9th vol of 0.13 through Whatman no. 1 paper, leaving a faint yellow-green residue. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "ad- Abbreviations: HF, Hageman factor; PTA, plasma thromboplastin vertisement" in accordance with 18 U. S. C. §1734 solely to indicate antecedent; PK, plasma prekallikrein; HMWK, high molecular weight this fact. kininogen; CT, clotting time; PTT, partial thromboplastin time. 958 Downloaded by guest on September 28, 2021 Medical Sciences: Ratnoff and Saito Proc. Natl. Acad. Sci. USA 76 (1979) 959 Sephadex-ellagic acid was prepared by swelling Sephadex Table 1. Effect of Sephadex-ellagic acid upon the coagulant G-10, G-15, G-25, G-100, G-150 or G-200 (Pharmacia) in'A3 vol properties of HF in plasma of buffer for 1 hr. The supernatant was decanted and the pro- Addition to Clotting activity cess was repeated twice, with 0.02% sodium azide added to the PTA-deficient Centrolex Kaolin/Centrolex third wash. The swollen Sephadex was stored at 40C until used. plasma Sec Units/ml Sec Units/ml Ten milliliters settled volume of Sephadex was mixed with 30 ml of 0.1 mM ellagic acid, stirred for several min, and allowed Sephadex-ellagic acid 80.6 0.48 77.9 0.57 to settle, and the supernatant was decanted. Approximately 25% Sephadex-buffer >300 <0.01 63.5 > 1.0 of the ellagic acid was adsorbed to the Sephadex, as estimated Two milliliters of Sephadex G-10-ellagic acid or Sephadex-buffer, by the clot-promoting properties of the supernatant after cen- washed 15 times, was mixed with 2.0 ml of human PTA-deficient trifugation at 2000 X g for 10 min, relative to fresh solutions plasma, then diluted to 4 ml with-buffer and centrifuged, and a sample of ellagic acid, using the partial thromboplastin time (PTT) of of the supernatant was tested on HF-deficient substrate plasma normal plasma as an indicator. The Sephadex-ellagic acid was without further dilution for activated HF (Centrolex added) or total supernatant HF (kaolin/Centrolex added), -incubating the final mixture 8 min washed 6-15 times with 100 ml of buffer, with the before recalcification. Clotting activity was compared to that ofpooled discarded each time after the gel had settled; the last buffer normal plasma that was diluted serially with buffer and assayed for contained 0.02% sodium azide. Sephadex-ellagic acid retained total HF without exposure to Sephadex-ellagic acid or Sephadex- its clot-promoting properties for at least a month at 4VC. The buffer. Clotting activity is expressed both as CT (in sec) and in units 15th wash contained less than 0.1 sM ellagic acid, measured of HF/ml in comparison to the standard. The PTA-deficient plasma by the PTT after centrifugation. Sephadex-buffer was prepared had a titer of 0.78 unit of HF/ml. in the same way except for substitution of buffer for ellagic acid. observed when the treated PTA-deficient plasma was incubated Purified HF (22) varied in specific activity from 63 to 83 with HF-deficient plasma for 8 min before recalcification units/mg of protein. Partially purified PK contained 1.25 (Table 1). The same result was obtained with bovine PTA- coagulant units of PK per ml (3.2 units/mg of protein) and no deficient plasma and also when the supernatant, diluted plasma detectable contamination with other clotting factors; the bulk was recentrifuged at 30,000 X g for 15 min to ensure that no of extraneous protein was IgG (13). Sephadex-ellagic acid was transferred to the substrate plasma. Bovine serum albumin (crystallized, Pentex, Miles) was Sephadex G-25-, G-100-, G-150-, and G-200-ellagic acid were dissolved at a concentration of 1% in buffer. successively less effective, while Sephadex-buffer, without el- Clotting factors in plasma were titrated by a modified ka- lagic acid, was not clot-promoting.
Load more

Recommended publications
  • Activation of the Plasma Kallikrein-Kinin System in Respiratory Distress Syndrome
    003 I-3998/92/3204-043 l$03.00/0 PEDIATRIC RESEARCH Vol. 32. No. 4. 1992 Copyright O 1992 International Pediatric Research Foundation. Inc. Printed in U.S.A. Activation of the Plasma Kallikrein-Kinin System in Respiratory Distress Syndrome OLA D. SAUGSTAD, LAILA BUP, HARALD T. JOHANSEN, OLAV RPISE, AND ANSGAR 0. AASEN Department of Pediatrics and Pediatric Research [O.D.S.].Institute for Surgical Research. University of Oslo [L.B.. A.O.A.], Rikshospitalet, N-0027 Oslo 1, Department of Surgery [O.R.],Oslo City Hospital Ullev~il University Hospital, N-0407 Oslo 4. Department of Pharmacology [H. T.J.],Institute of Pharmacy, University of Oslo. N-0316 Oslo 3, Norway ABSTRAm. Components of the plasma kallikrein-kinin proteins that interact in a complicated way. When activated, the and fibrinolytic systems together with antithrombin 111 contact factors plasma prekallikrein, FXII, and factor XI are were measured the first days postpartum in 13 premature converted to serine proteases that are capable of activating the babies with severe respiratory distress syndrome (RDS). complement, fibrinolytic, coagulation, and kallikrein-kinin sys- Seven of the patients received a single dose of porcine tems (7-9). Inhibitors regulate and control the activation of the surfactant (Curosurf) as rescue treatment. Nine premature cascades. C1-inhibitor is the most important inhibitor of the babies without lung disease or any other complicating contact system (10). It exerts its regulatory role by inhibiting disease served as controls. There were no differences in activated FXII, FXII fragment, and plasma kallikrein (10). In prekallikrein values between surfactant treated and non- addition, az-macroglobulin and a,-protease inhibitor inhibit treated RDS babies during the first 4 d postpartum.
    [Show full text]
  • High Molecular Weight Kininogen Is an Inhibitor of Platelet Calpain
    High molecular weight kininogen is an inhibitor of platelet calpain. A H Schmaier, … , D Schutsky, R W Colman J Clin Invest. 1986;77(5):1565-1573. https://doi.org/10.1172/JCI112472. Research Article Recent studies from our laboratory indicate that a high concentration of platelet-derived calcium-activated cysteine protease (calpain) can cleave high molecular weight kininogen (HMWK). On immunodiffusion and immunoblot, antiserum directed to the heavy chain of HMWK showed immunochemical identity with alpha-cysteine protease inhibitor--a major plasma inhibitor of tissue calpains. Studies were then initiated to determine whether purified or plasma HMWK was also an inhibitor of platelet calpain. Purified alpha-cysteine protease inhibitor, alpha-2-macroglobulin, as well as purified heavy chain of HMWK or HMWK itself inhibited purified platelet calpain. Kinetic analysis revealed that HMWK inhibited platelet calpain noncompetitively (Ki approximately equal to 5 nM). Incubation of platelet calpain with HMWK, alpha-2- macroglobulin, purified heavy chain of HMWK, or purified alpha-cysteine protease inhibitor under similar conditions resulted in an IC50 of 36, 500, 700, and 1,700 nM, respectively. The contribution of these proteins in plasma towards the inhibition of platelet calpain was investigated next. Normal plasma contained a protein that conferred a five to sixfold greater IC50 of purified platelet calpain than plasma deficient in either HMWK or total kininogen. Reconstitution of total kininogen deficient plasma with purified HMWK to normal levels (0.67 microM) completely corrected the subnormal inhibitory activity. However, reconstitution of HMWK deficient plasma to normal levels of low molecular weight kininogen (2.4 microM) did not fully correct the subnormal calpain inhibitory capacity […] Find the latest version: https://jci.me/112472/pdf High Molecular Weight Kininogen Is an Inhibitor of Platelet Calpain Alvin H.
    [Show full text]
  • The Characteristic Normalization of the Severely Prolonged Aptt Following Increased Preincubation Time Is Due to Autoactivation of Factor XII
    Thrombosis Research 105 (2002) 463–470 Regular Article Prekallikrein deficiency: The characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII Lars M. Asmis*, Irmela Sulzer, Miha Furlan, Bernhard La¨mmle Central Hematology Laboratory, University of Bern, Inselspital, Bern CH 3010, Switzerland Received 8 November 2001; received in revised form 14 December 2001; accepted 28 January 2002 Accepting Editor: J. Meier Abstract Hereditary plasma prekallikrein (PK) deficiency was diagnosed in a 71-year-old man with an 8-year history of osteomyelofibrosis. PK deficiency was suspected in view of a severely prolonged activated partial thromboplastin time (aPTT) that nearly normalized following prolonged preincubation (10 min) of patient plasma with kaolin–inosithin reagent. Hereditary PK deficiency was demonstrated by very low PK values in the propositus (PK clotting activity 5%, PK amidolytic activity 5%, PK antigen 2% of normal plasma, respectively) and half normal PK values in his children. Normalization of a severely increased aPTT ( > 120 s) after prolonged preincubation with aPTT reagent occurred in plasma deficient in PK but not in plasma deficient in factor XII (FXII), high-molecular-weight kininogen (HK), factor XI (FXI), factor IX, factor VIII, Passovoy trait plasma or plasma containing lupus anticoagulant. Autoactivation of FXII in PK-deficient plasma in the presence of kaolin paralleled the normalization of aPTT. Addition of OT-2, a monoclonal antibody inhibiting activated FXII, prevented the normalization of aPTT. We conclude that the normalization of a severely prolonged aPTT upon increased preincubation time (PIT), characteristic of PK deficiency, is due to FXII autoactivation.
    [Show full text]
  • Identification of Prekallikrein and High-Molecular-Weight Kininogen As a Complex in Human Plasma (Hageman Factor/Bradykinin Generation/Contact Activation) ROBERT J
    Proc. Nati. Acad. Sci. USA Vol. 73, No. 11, pp. 4179-4183, November 1976 Immunology Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma (Hageman factor/bradykinin generation/contact activation) ROBERT J. MANDLE*, ROBERT W. COLMANt, AND ALLEN P. KAPLAN** * Allergic Diseases Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20014; and t The Coagulation Unit of the Hematology-Oncology Section, Department of Medicine, University of Pennsylvania, Philadelphia, Pa. 19104 Communicated by K. Frank Austen, August 19, 1976 ABSTRACT Prekallikrein and high-molecular-weight ki- (Fletcher trait) was a gift from Dr. C. Abildgaard (University ninogen were found associated in normal human plasma at a of California, Davis, Calif.). Kininogen-deficient plasma was molecular weight of 285,000, as assessed by gel filtration on obtained from Ms. Williams and was collected as described Sephadex G-200. The molecular weight of prekallikrein in plasma that is deficient in high-molecular-weight kininogen was (3). 115,000. This prekallikrein could be isolated at a molecular Preparation of Plasma Proteins. Fresh plasma used for the weight of 285,000 after plasma deficient in high-molecular- isolation of prekallikrein and HMW kininogen was collected weight kininogen was combined with plasma that is congeni- in 0.38% sodium citrate. Hexadimethrine bromide (3.6 mg) in tally deficient in prekallikrein. Addition of purified 125I-labeled 0.1 ml of 0.15 M saline was added for each 10 ml of blood prekallikrein and high-molecular-weight kininogen to the re- drawn.
    [Show full text]
  • Anti-Prekallikrein Heavy Chain Antibody [13G11] (ARG54564)
    Product datasheet [email protected] ARG54564 Package: 50 μg anti-Prekallikrein Heavy Chain antibody [13G11] Store at: -20°C Summary Product Description Mouse Monoclonal antibody [13G11] recognizes Prekallikrein Heavy Chain Tested Reactivity Hu Tested Application ELISA, IHC, WB Specificity This antibody specifically recognizes in human plasma two variants (88 kDa and 85 kDa) of prekallikrein and its activation products kallikrein (88 kDa and 85 kDa), the complexes formed by kallikrein with its endogenous inhibitors C1 inhibitor, alpha-2-macroglobulin and antithrombin III, and 45 kDa prekallikrein/kallikrein fragment(s). It also recognizes prekallikrein and its activation products in chimpanzee, rhesus, and baboon plasmas. The epitope for this antibody, located on the prekallikrein/kallikrein heavy chain, is involved in the interaction between prekallikrein and factor XIIa. This antibody inhibits prekallikrein activation in human and rhesus plasmas by approximately 60-80% and 55%, respectively. This antibody does not cross-react with tissue kallikrein. Host Mouse Clonality Monoclonal Clone 13G11 Isotype IgG1 Target Name Prekallikrein Heavy Chain Antigen Species Human Immunogen Human plasma prekallikrein. Conjugation Un-conjugated Alternate Names Williams-Fitzgerald-Flaujeac factor; Kallidin II; High molecular weight kininogen; KNG; Fitzgerald factor; Alpha-2-thiol proteinase inhibitor; BDK; BK; Kininogen-1; HMWK; Kallidin I; Ile-Ser-Bradykinin Application Instructions Application Note This antibody may be used in ELISA and Western blots to identify/quantitate prekallikrein and its activation products in plasmas of humans, chimpanzees, rhesus monkeys, and baboons. Other applications are under investigation. NOTE: Prekallikrein activation may occur with repeated freezing/thawing (3x or more) of plasma samples obtained from humans or other primates.
    [Show full text]
  • Prekallikrein Deficiency
    Prekallikrein deficiency Description Prekallikrein deficiency is a blood condition that usually causes no health problems. In people with this condition, blood tests show a prolonged activated partial thromboplastin time (PTT), a result that is typically associated with bleeding problems; however, bleeding problems generally do not occur in prekallikrein deficiency. The condition is usually discovered when blood tests are done for other reasons. A few people with prekallikrein deficiency have experienced health problems related to blood clotting such as heart attack, stroke, a clot in the deep veins of the arms or legs ( deep vein thrombosis), nosebleeds, or excessive bleeding after surgery. However, these are common problems in the general population, and most affected individuals have other risk factors for developing them, so it is unclear whether their occurrence is related to prekallikrein deficiency. Frequency The prevalence of prekallikrein deficiency is unknown. Approximately 80 affected individuals in about 30 families have been described in the medical literature. Because prekallikrein deficiency usually does not cause any symptoms, researchers suspect that most people with the condition are never diagnosed. Causes Prekallikrein deficiency is caused by mutations in the KLKB1 gene, which provides instructions for making a protein called prekallikrein. This protein, when converted to an active form called plasma kallikrein in the blood, is involved in the early stages of blood clotting. Plasma kallikrein plays a role in a process called the intrinsic coagulation pathway (also called the contact activation pathway). This pathway turns on (activates) proteins that are needed later in the clotting process. Blood clots protect the body after an injury by sealing off damaged blood vessels and preventing further blood loss.
    [Show full text]
  • Plasma Prekallikrein Determination of Prekallikrein in Plasma with a Chromogenic Substrate
    Plasma Prekallikrein Determination of prekallikrein in plasma with a chromogenic substrate Measurement Principle The activation of plasma prekallikrein is mediated by the Hageman factor on negatively charged surfaces and in presence of HMW kininogen. A number of methods have been described for the activation of prekallikrein. This method is related to the use of human FXIIa (Hageman factor) acting as prekallikrein activator. However, the assay should be validated with respect to the particular activator used. Following the activation, the plasma kallikrein formed catalyses the hydrolysis of p-nitroaniline (pNA) from the chromogenic substrate H-D-Pro-Phe-Arg-pNA (CS-31(02)). The rate at which pNA is released is measured photometrically at 405 nm. This can be followed on a recorder (initial rate method) or read after stopping the reaction with acetic acid (acid stopped method). The concentration of prekallikrein is calculated by using standards prepared from normal plasma. Contact activation F XII FXIIa FXIIa + HMW kininogen Prekallikrein Kallikrein Kallikrein H-D-Pro-Phe-Arg-pNA + H2O H-D-Pro-Phe-Arg-OH + pNA Reagents 1. Chromogenic substrate e.g. CS-31(02), 25 mg; art.no.: 229031 Reconstitute with 20 mL of distilled water. 2. Human Factor XIIa - Prekallikrein Activator, 100 ng; art.no.: EZ012A Reconstitute with 5 mL of Tris-buffer (3). 3. Tris-Buffer pH 7.8; art.no.: AR103A (10 mL) 4. Calibration Plasma; art.no.: CCNRP-05 (25x0.5 mL), CCNRP-10 (25x1.0 mL) 5. Acetic acid, 20% or citric acid 2%, used in the acid-stopped method only. Specimen collection Blood (9 vol) is mixed with 0.1 mol/L sodium citrate (1 vol) and centrifuged at 2000 x g for 20 minutes at 15-25°C.
    [Show full text]
  • Pro-Urokinase and Prekallikrein Are Both Associated with Platelets
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 318, number 3, 317-321 FEBS 12193 March 1993 0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 Pro-urokinase and prekallikrein are both associated with platelets Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis Victor Gurewich, Michael Johnstone, Jean-Pierre Loza and Ralph Pannell Vascular Research Laboratory, Institute for the Prevention of Cardiovascular Disease, Deaconess Hospital, Harvard Medical School, 185 Pilgrim Road, Boston, MA 02215. USA Received 5 January 1993 The contact-dependent intrinsic pathway of fibrinolysis involving factor XII, prekallikrein (PK) and pro-urokinase (pro-UK) remains poorly understood. Casein autography of washed, intact platelets revealed both PK and pro-UK. Accordingly, platelets may mediate physiological thrombolysis by this pathway since factor XIIa activates PK and kallikrein activates pro-UK. Acid washing dissociated PK but not pro-UK from platelets. Exogenous pro-UK was specifically incorporated by platelets from the ambient fluid and similarly could not be dissociated from intact platelets. Therefore, platelets may also mediate an effect from therapeutically administered pro-UK by prolonging its half-life. Pro-urokinase: Prekallikrein; Platelet; Fibrinolysis 1. INTRODUCTION of pro-UK is less than 2 r&ml [ 121 and it does not bind to fibrin [13]. Pro-urokinase (pro-UK) is a plasminogen proactiva- These studies of pro-UK-mediated fibrinolysis, and tor which is activated to urokinase (UK) by both plas- most others in the literature, were conducted in platelet- min [l] and kallikrein [2].
    [Show full text]
  • COVID-19 Biomarkers for Severity Mapped to Polycystic Ovary Syndrome
    Moin et al. J Transl Med (2020) 18:490 https://doi.org/10.1186/s12967-020-02669-2 Journal of Translational Medicine LETTER TO THE EDITOR Open Access COVID-19 biomarkers for severity mapped to polycystic ovary syndrome Abu Saleh Md Moin1, Thozhukat Sathyapalan2, Stephen L. Atkin3† and Alexandra E. Butler1*† To the Editor, diagnostic criteria. Proteins that were identifed as being altered in COVID-19 disease for vessel damage (16 pro- Large scale multi-omics analysis has identifed signif- teins), platelet degranulation (11 proteins), coagula- cant diferences in the biomarkers between COVID-19 tion cascade (24 proteins) and acute phase response (9 disease and control subjects [1]. Tese protein panels tar- proteins), shown in Table 1, were determined by Slow get biological processes involved in vessel damage, plate- Of-rate Modifed Aptamer (SOMA)-scan plasma pro- let degranulation, the coagulation cascade and the acute tein measurement [6]. Statistics were performed using phase response [1], with greater protein changes depend- Graphpad Prism 8.0. ent on the COVID-19 severity. However, it is observed As reported previously [2], cohorts were age-matched, that in metabolic conditions such as polycystic ovary but PCOS women had increased insulin resistance, syndrome expressed proteins difer compared to control androgens and CRP (p < 0.001): systolic and diastolic women [2] and PCOS patients have increased platelet blood pressure, and waist circumference were higher aggregation and decreased plasma fbrinolytic activity, (p < 0.05). resulting in
    [Show full text]
  • Plasma Prekallikrein a Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes Ayad A
    Plasma Prekallikrein A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes Ayad A. Jaffa,1 Ramon Durazo-Arvizu,2 Deyi Zheng,2 Daniel T. Lackland,2 Sujata Srikanth,3 W. Timothy Garvey,1,4 Alvin H. Schmaier,3 and the DCCT/EDIC Study Group5 The relevance and significance of the plasma kallikrein/ 2) PK levels are independently correlated with AER and kinin system as a risk factor for the development of are categorically elevated in patients with macroalbu- vascular complications in diabetic patients was ex- minuria; and 3) although the positive correlation be- plored in a cross-sectional study. We measured the tween PK and AER within the subgroups of patients circulating levels of plasma prekallikrein (PK) activity, with microalbuminuria suggest that PK could be a -factor XII, and high؊molecular weight kininogen in the marker for progressive nephropathy, longitudinal stud plasma of 636 type 1 diabetic patients from the Diabetes ies will be necessary to address this issue. Diabetes 52: Control and Complications Trial/Epidemiology and Dia- 1215–1221, 2003 betes Intervention and Complications Study cohort. The findings demonstrated that type 1 diabetic patients with blood pressure >140/90 mmHg have increased PK levels compared with type 1 diabetic patients with blood ypertension is a common comorbid disease of pressure <140/90 (1.53 ؎ 0.07 vs. 1.27 ؎ 0.02 units/ml; diabetes, and is a major risk factor for the P < 0.0001). Regression analysis also determined that development of macrovascular and microvas- plasma PK levels positively and significantly correlated cular complications of diabetes (1–3).
    [Show full text]
  • Prekallikrein Heavy Chain Monoclonal Antibody
    Prekallikrein Heavy Chain Monoclonal Antibody ORDERING INFORMATION Catalog no.: 19901 (clone 13G11) Format: 200ug Protein G-purified antibody in PBS, pH 7.4. BACKGROUND Human prekallikrein, a serine protease zymogen, is present in plasma as two variants, 88kDa and 85kDa, probably due to different carbohydrate content. Approximately 75% of the total prekallikrein in plasma is noncovalently associated with high molecular weight kininogen (HMWK). HMWK mediates binding of prekallikrein to a negatively-charged surface which is required for its optimal activation to kallikrein by activated factor XII. Although kallikrein light and heavy chains can behave as functionally independent domains, the interaction between these two chains is essential for full biologic activity. SPECIFICATION SUMMARY Antigen: Purified human prekallikrein. Accession nos.: AAA60153, P03952.1 Gene ID: 125184 Host Species: Mouse Antibody Class: IgG1 Specificity: This antibody recognizes two variants of prekallikrein in human plasma, 88kDa and 85kDa, and its activation products kallikrein, the complexes formed by kallikrein with its endogenous inhibitors C1 inhibitor, alpha-2-macroglobulin and antithrombin III, and 45kDa prekallikrein/kallikrein fragments. It also recognizes prekallikrein and its activation products in chimpanzee, rhesus, and baboon plasmas. The epitope for this antibody is located on the prekallikrein/kallikrein hevy chain and is involved in the interaction between prekallikrein and factor XIIa. This antibody inhibits prekallikrein activation in human and rhesus plasmas by ~60- 80% and 55%, respectively. This antibody does not cross-react with tissue kallikrein. APPLICATIONS Immunoblotting: use at 1-5ug/ml. Bands of ELISA: use at 5-10ug/ml with prekallikrein 85kDa and 88kDa are detected. sample bound to ELISA plates.
    [Show full text]
  • Kallikrein Directly Interacts with and Activates Factor IX, Resulting in Thrombin Generation and Fibrin Formation Independent of Factor XI
    Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI Katherine J. Kearneya,1, Juliet Butlera,1, Olga M. Posadaa, Clare Wilsona, Samantha Heala, Majid Alia, Lewis Hardya, Josefin Ahnströmb, David Gailanic, Richard Fosterd, Emma Hethershawa, Colin Longstaffe, and Helen Philippoua,2 aLeeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, United Kingdom; bFaculty of Medicine, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, W12 0NN London, United Kingdom; cDivision of Hematology/Oncology, The Vanderbilt Clinic, Vanderbilt University, Nashville, TN 37232; dSchool of Chemistry, University of Leeds, LS2 9JT Leeds, United Kingdom; and eDivision of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom Edited by Barry S. Coller, The Rockefeller University, New York, NY, and approved December 3, 2020 (received for review July 15, 2020) Kallikrein (PKa), generated by activation of its precursor prekallikrein generated stimulates the intrinsic pathway of coagulation by ac- (PK), plays a role in the contact activation phase of coagulation and tivating FXI, which then converts FIX to FIXa, and FIXa acti- functions in the kallikrein-kinin system to generate bradykinin. vation of FX to FXa, at which point the intrinsic and extrinsic The general dogma has been that the contribution of PKa to the pathways converge. coagulation cascade is dependent on its action on FXII. Recently In addition to its role in the intrinsic pathway of coagulation, this dogma has been challenged by studies in human plasma PKa also functions in the kallikrein-kinin system by cleaving HK, showing thrombin generation due to PKa activity on FIX and also releasing the vasoactive peptide bradykinin (BK) (15).
    [Show full text]